New Century Health and Neighborhood Health Plan of Rhode Island study finds increased hypofractionation uptake

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from New Century Health and Neighborhood Health Plan of Rhode Island presented findings from their efforts to increase adoption of hypofractionation in breast cancer patients at the National Comprehensive Cancer Care Network conference, on March 31.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy. 

Login